QUALITY REVOLUTION?

ANNUAL CONFERENCE
The Midland Hotel, Manchester 7-9 November 2012
The BARQA 2012 Conference Programme Committee invites you to attend the 2012 Conference in Manchester with the theme ‘Quality Revolution?’, a full conference programme consisting of plenary and parallel sessions, QA Clinics, workshops and excellent networking opportunities.

Following feedback from last year’s conference we have restructured the programme to incorporate the QA Clinics into the main programme on Wednesday and endeavoured to make the parallel presentations more interactive.

So please take a look through this full programme and visit the BARQA website www.barqa.com to book online and find out further information. Alternatively complete the enclosed registration form to book your place at this prestigious event.

When booking online or using the registration form please ensure you tick all your required streams you wish to attend to avoid disappointment.

PRE-CONFERENCE TRAINING
This year we are running some pre-conference training at The Midland Hotel, Manchester, before the main conference begins.

Four of our Professional Development courses are on offer as follows:

- **Good Clinical Practice Regulatory Inspections**
  2 day course – 5th-6th November 2012

- **Systems Audit**
  2 day course – 5th-6th November 2012

- **Implementing Good Clinical Laboratory Practice**
  2 day course – 5th-6th November 2012

- **Managing an Audit Programme**
  One day course – 6th November 2012

**SPECIAL OFFER**
20% DISCOUNT

A discount of 20% is available on these courses if booking a Full Delegate Conference Package at the same time. For full details of these course see the Pre-Conference Training Brochure or visit www.barqa.com
THE MIDLAND HOTEL, MANCHESTER

The iconic Midland Hotel, conveniently located in the heart of the city centre, is a Grade II listed treasure oozing luxury, comfort and style. Over the course of its 100 year history, The Midland Hotel has welcomed many a king, queen and celebrity. The red-bricked Victoriana that Manchester is famous for is perfectly captured in the architecture of the hotel. The building’s characteristic style continues inside, where you’ll find opulent decor, rich fabrics and shimmering chandeliers.

The hotel boasts 312 spacious bedrooms and two excellent restaurants including the two AA Rosette award-winning French Restaurant. Free internet access is now available throughout The Midland. For the energetic, take a refreshing swim or a gentle workout in the hotel’s superb leisure club.

The hotel is located a mere 200 metres from Oxford Road Station, 800 metres from Piccadilly Station and neighbouring Manchester Central and only a short walk into the famous shopping area of Manchester including the Arndale Centre.

Manchester is never short on things to do. Indeed, within easy striking distance of the hotel are all manner of world-class venues offering enough opportunities for enlightenment and entertainment. There is a sophisticated nightlife, great music and many tempting shops and of course the Wheel of Manchester with its incredible views of ever changing Manchester. In fact Manchester has a culture all of its own.
QUALITY REVOLUTION?

09.00  Conference registration
10.00  Opening address
       Rachel Hodges, BARQA Chair

SESSION 1: THE NEW REVOLUTION
Chair: Rachel Hodges, BARQA Chair

10.15  Personal Best
       Marc Woods, Paralympic Gold Medalist

• Adapting to challenges
• Delivering excellence
• Personal responsibility
• Teamwork

11.15  Coffee

SESSION 2: THE NEW REVOLUTION
Chair: Rachel Hodges, BARQA Chair

11.45  The human factor and safety culture: Why the fuss?
       Brian Edwards, NDA Regulatory Science Ltd

• Evidence base for what constitutes a safe system
• Relationship between quality, innovation and safety
• Tools for adapting human factors to a process
• The journey towards safety culture

12.30  BARQA EGM and AGM including presentation of awards
13.00  Lunch
QA CLINICS
Following on from delegate feedback the popular QA Clinics have now been moved into the main conference programme. So please drop in to these Clinics to meet and discuss ‘hot topics’ with experts in their fields, get advice on tricky QA issues, sit in on discussions regarding the latest QA concerns and developments or bring your own question to the Clinic for discussion.

If you have any questions/topics you would like covered at any of these Clinics, please email these to qaclinics@barqa.com prior to the conference. Please state which QA Clinic the question/topic is for. So please come along and drop in for a lively discussion!

There are four separate QA Clinics in each of Sessions 3 and 4 as follows:

SESSION 3: QA CLINICS 14.00-15.00

14.00 Good Clinical Practice/Pharmacovigilance Practice
• New PV regulations – impact on GCP/PV QA interface
• DSURs
• Investigator, EC & RA safety reporting
• GCP & PV inspections – common areas of interest
• Medical monitoring & 24/7 coverage

14.00 Good Laboratory Practice/Animal Health
Regulatory Update Presentation
OECD GLP Discussion Group – inconsistencies within GLP monitoring authorities and emerging technologies.

14.00 Computing
The clinic will cover any computing issues/questions delegates wish to discuss. This could include:
• A year on – the impact of Annex 11
• Should different software development methodologies impact your validation approach?
• Management of outsourced suppliers
• Recent inspection experiences from a computing perspective – what are the inspectors focussing on?

14.00 NHS, research labs and start up companies
(Outreach Working Party)
• How do you run a quality system in a busy NHS ward?
• How do you get consistency in GCP procedures across a large district hospital?
• How do you run a quality system in a NHS laboratory and in a university laboratory?
• Why should research labs have quality systems?
• What do the HTAs quality standards expect from a quality system?
• How does the Research Support Services Framework help me be compliant on a clinical trial?

15.00 Tea

SESSION 4: QA CLINICS 15.30-17.00

15.30 Good Clinical Practice
The clinic will cover ‘hot topics’ at the time of the conference including regulation updates and inspection trends.

15.30 Good Laboratory Practice/Animal Health
Topics may include:
• GCLP
• Archiving electronic raw data
• Analytical method validation – EMA guidance
• Auditing GCP studies conducted in GLP facilities
• Use of non-GLP facilities

15.30 Medical Devices Working Party
Do you know:
• Whether your device continues to be effective and is used correctly in the field?
• What event data you need to collect in your clinical investigation?
• How to collect up-to-date vigilance data?
• What is the difference between a clinical evidence report and a final study report?
• What harmonised standards are and where they are listed?
• Which standards are relevant to medical device labelling and what the requirements are?
• For innovative products such as nanoproduct: How to determine if your product is an IMP or an IMD? Once you’ve figured that out, how to classify it?

Get answers to these and other questions at the clinic.

15.30 Good Pharmacovigilance Practice
EU Directive 2010/84/EU – a chance to discuss
Please bring all questions relating to your ‘hot topics’ to discuss at this open forum.

17.00 Delegates drinks reception
A chance for delegates to network with their fellow colleagues and renew old acquaintances.
### SESSION 1: WORKING ON WAYS FORWARD
**Chair:** Colin Wilsher, GCP Committee Chair

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.00</td>
<td>Practical guide to non-commercial and industry collaboration</td>
<td>Jane Tucker, Clinical Research Computer Systems Validation Working Party</td>
</tr>
<tr>
<td></td>
<td>• Collaborations between academia and industry are causing headaches all round</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Research on the root cause of the problem</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Actions taken so far to produce guidance</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Where do we go from here?</td>
<td></td>
</tr>
<tr>
<td>9.45</td>
<td>eCRF Deployment considerations and identification of audit targets for EDC studies</td>
<td>Anna Tillmann, Theorem Clinical Research and Thana Subramanian, GE Healthcare Medical Diagnostics</td>
</tr>
<tr>
<td></td>
<td>• Introduction to validation of deploying an eCRF</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Addressing the quality aspects to system specification, qualification, training and password management and security aspects</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• How to identify the audit targets related to these risks and when and how to practically conduct the audits</td>
<td></td>
</tr>
<tr>
<td>10.30</td>
<td>Coffee</td>
<td></td>
</tr>
</tbody>
</table>

### SESSION 2: TOGETHER IN ELECTRIC DREAMS
**Chair:** Colin Wilsher, GCP Committee Chair

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.00</td>
<td>Clinical electronic data workshop – Is the technology evolving faster than we are?</td>
<td>Wendy Koc, Gilead Sciences EMEA; Barbara Kay-Farrow, Covance; Matt Jones, Johnson &amp; Johnson</td>
</tr>
<tr>
<td></td>
<td>This will be an interactive session so delegates are encouraged to bring current issues and suggested solutions for discussion with the aim of creating recommended ‘best practices and considerations’.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• E-Source – iPads, iPhones, IDont know how they work or how to audit them. What is the source?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• EMRs – compare and contrast current experiences of EMRs in use</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• eTMFs – does paper still play a role? Can we reconstruct a study from just the eTMF in the future?</td>
<td></td>
</tr>
<tr>
<td>12.30</td>
<td>Lunch</td>
<td></td>
</tr>
</tbody>
</table>

### SESSION 1: EVOLUTION OR REVOLUTION
**Chair:** Tracy Gilbert, Huntingdon Life Sciences

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.00</td>
<td>A GLP QA Programme fit for purpose</td>
<td>Lesley Graham, MHRA</td>
</tr>
<tr>
<td></td>
<td>• What are the limitations with the current OECD and UK Guidance documents for QA?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• What does a proactive and effective GLP QA Programme look like</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• What does a risk-based GLP QA Programme need to consider?</td>
<td></td>
</tr>
<tr>
<td>9.45</td>
<td>Risk-based Quality Assurance – An industry perspective</td>
<td>Vanessa Grant, Huntingdon Life Sciences</td>
</tr>
<tr>
<td></td>
<td>• Background – UK Government &amp; Hampton review – The MHRA’s response</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• MHRA’s challenge to the QA profession</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• HLS’s response</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Report audit changes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Our basis for risk</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• A radical new inspection programme</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Next steps</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Reactions to date…</td>
<td></td>
</tr>
<tr>
<td>10.30</td>
<td>Coffee</td>
<td></td>
</tr>
</tbody>
</table>

### SESSION 2: EVOLUTION OR REVOLUTION
**Chair:** Tracy Gilbert, Huntingdon Life Sciences

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.00</td>
<td>Value added QA</td>
<td>Steve Rogers, Pfizer Animal Health</td>
</tr>
<tr>
<td></td>
<td>• Define and discuss some basic terms used in the risk management process</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describing and applying simple evaluation techniques to better enable organisations to focus resources on high value activities</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Explain how risk management may better improve the organisational decision making process</td>
<td></td>
</tr>
<tr>
<td>11.45</td>
<td>Disaster recovery</td>
<td>Kaneme Takahashi, Mitsubishi Chemical Medience</td>
</tr>
<tr>
<td></td>
<td>Disaster recovery following the Japanese earthquake – Our experiences</td>
<td></td>
</tr>
<tr>
<td>12.30</td>
<td>Lunch</td>
<td></td>
</tr>
</tbody>
</table>

### SESSION 1: ABILITY TO REVITALISE
**Chair:** Pam Bones, MSD Ltd

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.00</td>
<td>Implementation of the new pharmacovigilance legislation</td>
<td>Maria Wishart, GlaxoSmithKline</td>
</tr>
<tr>
<td></td>
<td>• Overview of new legislation including rationale and aims</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Key implementation challenges for industry</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Focus on the PV master file and EU risk management plans</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Impact on the QPPV role</td>
<td></td>
</tr>
<tr>
<td>9.45</td>
<td>MHRA PV Inspections in light of new EU PV legislation</td>
<td>Jonathan Rowell, MHRA</td>
</tr>
<tr>
<td></td>
<td>• Common MAH findings since July 2012</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• How are MAHs balancing new and old legislation during the transition</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Learnings for MAHs</td>
<td></td>
</tr>
<tr>
<td>10.30</td>
<td>Coffee</td>
<td></td>
</tr>
</tbody>
</table>

### SESSION 2: ABILITY TO REVITALISE
**Chair:** Pam Bones, MSD Ltd

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.00</td>
<td>PVQA audits and the impact of the new EU legislation</td>
<td>Katrien Solomé, UCB Pharma SA</td>
</tr>
<tr>
<td></td>
<td>• Oversight and management of the QMS for the PV system, the PV system quality plan and the role of PVQA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Revamping PVQA risk-based assessment tools in view of the new EU PV legislation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Impact of the new EU PV legislation on audit and capacity planning</td>
<td></td>
</tr>
<tr>
<td>11.45</td>
<td>Volume 9B – Revised or revitalised?</td>
<td>Kevin Woodward, TSGE Ltd</td>
</tr>
<tr>
<td></td>
<td>• Background to legislation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Summary of content of Volume 9B</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Main requirements</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Implications for marketing authorisation holders (MAHs)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Conclusions</td>
<td></td>
</tr>
<tr>
<td>12.30</td>
<td>Lunch</td>
<td></td>
</tr>
</tbody>
</table>
SESSION 3: STRIVING FOR GOLD
Chair: Glene Sandom, ICON Clinical Research

13.30 Evolving strategic roles of QA
Steve Berry, Johnson & Johnson; Claire Pope, ICON Clinical Research; Chris Shepherd, GlaxoSmithKline

Three key speakers from pharma and CRO presenting high level presentations on the evolving strategic roles of QA. Content includes, but not limited to:
- Where is clinical QA heading?
- Is risk-based audit strategy enough?
- Challenges – Impact of inspections

14.15 QA But not as we know it?
Louise Mawer
- Risk adaption – where science meets compliance
- The changing face of quality and the impact on the role of QA
- Being innovative, flexible and responsive…by design?

15.00 Tea

SESSION 4: STRIVING FOR GOLD
Chair: Glene Sandom, ICON Clinical Research

15.30 Hot topics in the evolution of GCP
MHRA speaker
- Risk adaptive approaches, where, now, next
- Evolution of the inspection of the TMF with increasing use of eTMF
- Update on the Agency’s Risk-Based Inspection Programme

16.15 A day in the life – Asia/Pacific Clinical QA
Hannah Chen, GlaxoSmithKline
- What are the challenges of clinical QA in Asia/Pacific?
- How is integration into international QA teams/departments achieved?
- Are there compromises to be made when working to international standards?
- What will the future look like?

19.00 Drinks reception
19.30 Gala dinner

SESSION 3: EVOLVE OR DIE
Chair: Tracy Gilbert, Huntingdon Life Sciences

13.30 Revolutionise the GLP Regulations – Workshop
BARQA GLP and Animal Health Committees

The world we live in is changing and so must we. We are faced with more emerging technologies than ever before. Are our current GLP regulations ready for change? How would you modernise the GLP regulations?

This interactive workshop will discuss areas for potential modernisation to include, but not limited to:
- QA
- Test and reference items
- Test systems
- Recording of raw data/data capture
- Storage and retention of records and materials
- Multi-site studies
- Use of non-GLP facilities

15.00 Tea

SESSION 4: EVOLVE OR DIE
Chair: Tracy Gilbert, Huntingdon Life Sciences

15.30 Revolutionise the GLP Regulations – Workshop continues
BARQA GLP and Animal Health Committees

19.00 Drinks reception
19.30 Gala dinner

SESSION 3: EVOLVING QUALITY BY DESIGN
Chair: Thierry Hamard, PV Focus

13.30 PV Audits – Workshop
Thierry Hamard, PV Focus; Andy Blackman, Transcript Partners LLP; Jonathan Rowell, MHRA

- Practical guidance on selected aspects of the pharmacological system in the light of the new EU PV legislations
- Clarification on the expectations of EU inspectorates
- Insight into the assignment of finding categories by inspectors

15.00 Tea

SESSION 4: EVOLVING QUALITY BY DESIGN
Chair: Thierry Hamard, PV Focus

15.30 PV Audit – Workshop continues
Thierry Hamard, PV Focus; Andy Blackman, Transcript Partners LLP; Jonathan Rowell, MHRA

19.00 Drinks reception
19.30 Gala dinner
Thursday 8 November 2012

SESSION 1: QUALITY CYCLE
Chair: Alan Dench, Clinical Compliance Services

9.00 What can go wrong with medical devices? – Case study
Kevin Butcher, SGS UK Ltd
- Problems with design and development
- Problems with production scale-up
- Problems with clinical investigations and post clinical follow up
- Problems with post market surveillance process

9.45 Regulatory challenges on drug device combinations
Henny Koch, Qimp Management Systems Ltd
- Combination products: A challenge for regulators and industry
- Risks due to differences in drug and device regulations during clinical development
- Drug or device, who is to blame in case of SAEs?
- Desirable harmonised regulations in line with concept 21CFR Part 4
- Harmonised quality systems approach aligning ICH Q10 and ISO 13485

10.30 Coffee

SESSION 2: QUALITY CYCLE
Chair: Alan Dench, Clinical Compliance Services

11.00 Device classification – Workshop
Fraser Smith, PPD
- Classification system for medical devices
- Options for conformity assessment
- CE Marking

12.30 Lunch

SESSION 1: EVOLUTION OR REVOLUTION
Chair: Meriam Lindsay, BTG Plc

9.00 GMP Legislation Update
Gordon MacDonald, Auxilium UK Ltd; Derek Murphy, MedImmune Limited
Legislation update on recent and future changes in GMP

9.45 What goes around comes around
Andrew Tudor, Pfizer
- Evolution of GMP
- What can we learn from the past
- Predicting the problems, rather than reacting
- GMP for the future industry

10.30 Coffee

SESSION 2: EVOLUTION OR REVOLUTION
Chair: Meriam Lindsay, BTG Plc

11.00 Easing the regulatory burden on industry
Michelle Rowson, MHRA
- Working with industry – New innovations
- The Red Tape Challenge
- Channels for discussion

11.45 GMP Jeopardy
Matilda Street, Idis Ltd
What to do when things go wrong.

12.30 Lunch

SESSION 1: HOLDING THE TORCH
Chair: Nichola Stevens, AstraZeneca

9.00 Auditing computerised system validation – Medal winning strategies
Chris Montgomery, QASYS Ltd
- The value of experience
- A risk-based approach
- Use of checklists
- Findings and observations

9.45 Achieving the gold standard: How much validation is enough?
A risk-based approach
Peter Falcon, AstraZeneca
- Approach for large complex systems
- Difference when applying principals to smaller systems
- How to apply the risk-based approach
- Possible pitfalls and advantages

10.30 Coffee

SESSION 2: HOLDING THE TORCH
Chair: Nichola Stevens, AstraZeneca

11.00 IT Validation: Contact sport or team game?
David Stokes, Business & Decision
This presentation will:
- Reflect on how project management and validation professionals are characterised as being on different teams
- Contrast how the traditional role of the IT validation manager often conflicts with the requirements for cost-effective, risk-based validation
- Demonstrate the importance of involving the validation manager as a key member of the project planning and project management team
- Identify where the modern validation manager can add additional coaching value to the implementation and support of computerised systems

11.45 The project team handed you the ‘torch’ – As a system owner what do you do now?
Thana Subramanian, GE Healthcare Medical Diagnostics
- Annex 11 & GAMP 5 requirements for a system owner
- Handling support organisations internally and externally
- Handover responsibilities from the project team
- Proposed governance model

12.30 Lunch
### SESSION 3: POWER TO THE PEOPLE
**Chair:** Kerry Bunyan, TMQA

**13.30** Checks and balances – Setting up a quality management system for human biological sample management in a complex environment  
*Lesley Stubbins, GlaxoSmithKline*
- Managing the risks/deviations from standards for human biological sample management (HBSM) globally
- Setting up a QMS to manage the risks
- How we prepared for our Human Tissues Authority (HTA) inspection
- Understanding some challenges and lessons learned along the way

**14.15** Evolution of a quality system: GMP viral vectors as vaccines for first-in-man clinical trials  
*Madeleine Fairweather, Clinical BioManufacturing Facility, The Jenner Institute, University of Oxford*
- QMS Development for bio-manufacturing
- Continuous improvement with examples from an existing manufacturing environment

**15.00 Tea**

### SESSION 4: POWER TO THE PEOPLE
**Chair:** Kerry Bunyan, TMQA

**15.30** Revolutions in laboratory research  
*Louise Handy, Handy Consulting Ltd*
- Research laboratories
- Clinical laboratories
- A journey through rebellion, transformation and quality circles

**16.15** QA in the clinical setting – A help or a hindrance?  
*Alex McLellan, Edinburgh Experimental Cancer Medicine Centre*
- Why QA in a clinical setting?
- What has to be done?
- How does one go about it?
- How do clinical staff cope?

**19.00 Drinks reception**
**19.30 Gala dinner**

### SESSION 3: EVOLUTION OR REVOLUTION
**Chair:** Meriam Lindsay, BTG Plc

**13.30** Practical applications of quality risk management  
*Ronnie Constable, Fisher Clinical Services UK Ltd*
QRM has been a regulatory expectancy in the pharmaceutical industry for some time in the EU but how does it manifest itself? What is risk and how is it measured? This presentation will attempt to answer these questions by considering the practical aspects of auditing vendors/suppliers; QP third party assessments for declarations; incident management (complaints, deviations, CAPAs), contamination control and business continuity planning.

**14.15** Don’t panic… keep calm and carry on – Workshop  
*Julie Giblin, Fisher Clinical Services UK Ltd*
Interactive workshop on issues relating to pharmaceutical development, quality risk management and quality management systems. An opportunity to meet and discuss issues with other delegates.

**15.00 Tea**

### SESSION 4: EVOLUTION OR REVOLUTION
**Chair:** Meriam Lindsay, BTG Plc

**15.30** Don’t panic… keep calm and carry on – Workshop continues  
*Julie Giblin, Fisher Clinical Services UK Ltd*

**16.15** ATMPs and the quality challenges  
*Janet Downie, Roslin Cells Ltd*
- What makes advanced therapy medicinal products (ATMPs) so different?
- The challenges
- Overcoming the challenges
- Hints and tips for successful development of an ATMP

**19.00 Drinks reception**
**19.30 Gala dinner**

### SESSION 3: HOLDING THE TORCH
**Chair:** Nichola Stevens, AstraZeneca

**13.30** Virtual revolution  
*Janet Nason, Altan*
- What is a virtual machine?
- Why use a virtual machine?
- When not to use a virtual machine
- Virtual machines – qualification on 2 levels

**14.15** Operating in the cloud, exploring regulatory myths and concerns  
*Christopher Reid, Integrity Solutions Limited*
This presentation will provide definitions of the various cloud scenarios and examine the benefits and risks associated with each solution. The presentation will share regulatory and industry concerns and expectations of cloud services providers and define controls to be considered when establishing cloud services.

**15.00 Tea**

### SESSION 4: HOLDING THE TORCH
**Chair:** Nichola Stevens, AstraZeneca

**15.30** A risk-based approach to computer system validation – Workshop  
*Nichola Stevens, AstraZeneca; Sarah Pickersgill, Celeron; Christopher Reid, Integrity Solutions Ltd; Peter Falcon, AstraZeneca*
An interactive session where teams will look at various scenarios and discuss what risk-based validation approach they would adopt.

**19.00 Drinks reception**
**19.30 Gala dinner**
### SESSION 1: WHAT MANCHESTER DOES TODAY, THE WORLD DOES TOMORROW

**Chair:** Louise Handy, new BARQA Chair

**9.30**  
**E-Archiving – ‘A never ending story’**  
Sarah Pickersgill, Celerion
- What are the compliance requirements?
- What are the processes/techniques available?
- Changes over the years
- Where do we go from here?

**10.30**  
Coffee

### SESSION 2: WHAT MANCHESTER DOES TODAY, THE WORLD DOES TOMORROW

**Chair:** Louise Handy, new BARQA Chair

**11.00**  
**Study and concept of TQM process controlled QA management**  
Henny Koch, QIMP Management Systems Ltd
- Introduction of process controlled QA management
- Alignment of TQM and lean concepts with ICH Q8/ Q9/ Q10 requirements
- Facilitation of continual improvement and CAPA control
- Awareness for quality monitoring and process reference following the pharmaceutical product life cycle
- One ICH Q10 and ISO 13485 compliant QA system for medicinal products and medical devices

**11.45**  
**Japanese Society for Quality Assurance (JSQA) Update**  
Teiki Iwaoka, Rika Ohnishi, JSQA

**12.00**  
Closing remarks  
Louise Handy, new BARQA Chair

---

**ROLL OUT THE RED CARPET**

Join us for a night with the stars, filled with the glitz and glamour of the big screen. For one night only The Midland Hotel is being transformed into Hollywood and BARQA’s VIP members are invited to attend.

---

**Thursday 8th November 2012**  
7.00pm Drinks Reception  
7.30pm Dinner  

Alexandra Suite  
The Midland Hotel

*Come as your favourite celebrity or Dress in your Hollywood best (black tie and ballgowns encouraged!)*
INFORMATION

GETTING TO MANCHESTER

BY CAR
From the North. From the M6 join the M61 at Preston. At the end of the M61, the motorway leads onto the M60, follow signs for M60 South and West towards the Trafford Centre. Continue onto the M602 and follow signs for the city centre and Manchester Central onto the A57. Turn left into Water Street and then left onto A56 Deansgate, then turn right on to Peter Street. The hotel is on the right hand side about 300 metres along.

From the South. Leave J19 of the M6 and follow signs to the M56, which later becomes the A5103. Follow city centre signs and at the end of the road, go straight over the roundabout, following signs for Manchester Central/Bridgewater Hall onto Medlock Street. Follow through the lights onto Lower Mosley Street. Pass the Bridgewater Hall on your right and the hotel is facing you.

BY RAIL
Trains predominately arrive at Manchester’s Piccadilly station located 0.5 miles from the hotel. Metrolink tram services run from within the station, the Eccles or Altrincham lines run to St. Peter’s Square station opposite the hotel. Alternatively, taxis and free city buses are available outside the station.

FROM MANCHESTER AIRPORT
Connect by bus, taxi or train. Six trains an hour (Monday to Saturday) run directly to Manchester Piccadilly station.

HOTEL DETAILS
The Midland Hotel
Peter Street
Manchester M60 2DS
Tel 0161 2363333
Email midlandevents@QHotels.co.uk
Web www.QHotels.co.uk

HOTEL ACCOMMODATION
Please note we have changed the way delegates book their hotel accommodation this year. BARQA hold an allocation of rooms at the hotel but all accommodation requirements are now made directly with the hotel and not through BARQA.

Special rates have been negotiated with the hotel as follows:

Single occupancy in a double room
£149 per person per night including breakfast

Double occupancy in a double room
£159 per room per night including breakfast

HOW TO BOOK
To obtain these special rates telephone the hotel’s central reservations team on 0845 0740060 quoting the code BARQA

There are many other hotels close to The Midland Hotel.